Imaging of nerves in the eyes may be used to differentiate between Parkinson’s disease and secondary forms of parkinsonism, a new study shows. The study, “Corneal confocal microscopy differentiates patients with secondary parkinsonism from idiopathic Parkinson’s disease,” was published in NPJ Parkinson’s Disease. Recommended…
Exposure to PM10 — air pollution that can come from wildfire smoke, construction dust, and vehicle exhaust — was associated with an increased risk of developing Parkinson’s disease in a recent Italian study. Part of the relationship was explained by blood levels of lipoprotein a, which is a protein…
Living within three miles of a golf course may increase the risk of developing Parkinson’s disease, possibly due to pesticide exposure, a study reported. The risk decreased with distance, the researchers found. Areas with water systems vulnerable to pesticide pollution from golf courses had a higher prevalence of Parkinson’s,…
People in the presymptomatic stages of Parkinson’s disease have distinct patterns of stimulated immune responses relative to those with clinically diagnosed disease or individuals who do not have Parkinson’s, according to a new study. In particular, the release of certain immune signaling proteins from isolated and stimulated immune cells…
The Parkinson’s Foundation now recognizes Dance for PD and Parkinson’s Pointe as accredited exercise education providers, a designation reserved for programs and courses that meet its standards to ensure that those with Parkinson’s disease receive quality and safe exercise programming to help manage their symptoms…
The Parkinson’s and Movement Disorder (PMD) Alliance, a U.S.-based nonprofit, is seeking participants willing to take part in an online survey about the experiences of patients and caregivers with off time in Parkinson’s disease. Off time, or periods when medication wears off and symptoms return,…
Angels on Call Homecare has received the 2025 Best of Home Care – Leader in Experience Award for their work providing care to people with Parkinson’s disease and dementia. “This award is a powerful reminder of our commitment to revolutionizing the experience of care,” Eric Dalton, vice president…
The U.S. Food and Drug Administrated (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) status to AAV-GAD, MeiraGTx’s gene therapy for Parkinson’s disease, the company has announced. The designation was granted based on data from three clinical studies showing the treatment eased motor symptoms and improved the quality…
Hillhurst Biopharmaceuticals said it’s been awarded $6.3 million to fund a Phase 2a clinical study to test the efficacy of HBI-002, its low-dose liquid formulation of carbon monoxide, in preserving dopaminergic neurons, those that are lost to Parkinson’s disease, with the goal of slowing or stopping disease progression. The…
The first three patients treated with ANPD001, a cell therapy for Parkinson’s disease, showed reduced motor symptoms and improved daily functioning over six months, without any serious side effects. That’s according to early data from the Phase 1/2a ASPIRO (NCT06344026) study, an open-label clinical trial testing the…
Get regular updates to your inbox.
